71 /100
HIGH RISK
Score updated May 30, 2026

BEAT — HeartBeam, Inc. Dilution Risk Tracker

Track BEAT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BEAT — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
100
💰 Cash Runway
85
📊 Float Risk
10
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
60%
💰 Capital Raise 73%
• Low cash runway: 4 months remaining
• Active shelf registration ($100M, 206% of market cap)
📉 Score Deterioration 50%
• Score rose 52 points recently (worsening)
• Score in HIGH risk zone (71/100)
🔄 Reverse Split 45%
• 50-day avg $1.00 approaching $1 threshold
• Only 4 months cash — financial pressure
🔔 Track BEAT — Get forecast alerts →

💹 Market Data

Market Cap$48.57M
Shares Outstanding55.51M
Float47.17M
Cash$2.04M
DebtN/A
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 35.7% shares (2025Q4 vs prior)
41 institutional holders · 4.56M shares
#1 VANGUARD GROUP INC 1.08M shares
#2 BlackRock, Inc. 892.2K shares
#3 UBS Group AG 453.7K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest2.59M
Days to Cover3.0
% of Float5.5%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Sep 30, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2023
4 INSIDER TRANSACTION Apr 16, 2026
4 INSIDER TRANSACTION Apr 16, 2026
4 INSIDER TRANSACTION Apr 16, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track BEAT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BEAT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for BEAT
📊 BEAT FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 BEAT Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.